Xiningshang published an interview with Eynos roughly half a year after the company was founded, covering its first series of immune cell-isolation kits and the decision to focus on one category.
This page summarises a media report about Eynos. Quoted wording — including terms such as "breakthrough", "on par with", "first" or "unique" — is the original reporter's language and is not a performance claim by the company. Product performance is defined by the manual and the measured data. All products are for research use only (RUO) and are not intended for diagnostic or therapeutic use.
The interview describes a deliberately narrow scope: magnetic cell separation first, with culture and differentiation reagents added only where the separation workflow required them.
It also covers the founding team's move from a university laboratory to a company, and the practical constraints — batch consistency, documentation and the cost of validation — that decide whether a reagent is usable outside the lab that made it.
The full report is published in Chinese: 中文原文. This page is an English summary prepared by Eynos.
Tell us your cell type, sample source and downstream assay — we will suggest an isolation route, a culture condition and the matching catalogue numbers.